Status:
COMPLETED
Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation
Lead Sponsor:
The University of Hong Kong
Collaborating Sponsors:
United Christian Hospital
Conditions:
Lupus Nephritis
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The optimal management of asymptomatic serological reactivation (ASR) in lupus nephritis (LN) patients remained undefined. This project aims to investigate the impact of pre-emptive treatment on disea...
Detailed Description
LN patients who presented with ASR \[defined as 1) increase in anti-dsDNA \>100 IU/mL , with or without drop in serum complement; or 2) increase in anti-dsDNA to higher than the normal range and \>2 t...
Eligibility Criteria
Inclusion
- Patients with biopsy-proven lupus nephritis who experienced an episode of Asymptomatic Serological Flare (ASF) as defined by:
- Increase in anti-dsDNA to \>100 IU/mL, with or without drop in serum complement levels OR
- Increase in anti-dsDNA to higher than the normal range and more than two times of the preceding value, with or without drop in serum complement levels
- AND
- Absence of renal or systemic manifestation of SLE.
Exclusion
- Patients who cannot provide informed consent.
- Patients whom the clinicians opined to have excessively high risk of infection or malignancy.
- Patients who are pregnant or lactating.
Key Trial Info
Start Date :
April 21 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04870359
Start Date
April 21 2016
End Date
March 31 2022
Last Update
December 16 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital, Hong Kong
Hong Kong, Hong Kong
2
United Christian Hospital
Hong Kong, Hong Kong